Please assess the completion status of the following clinical trial:

Trial Title: A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women age 18 and older~* Patients who are able and willing to give consent and able to attend all study visits~* Patients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions:~* Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician~* those for whom their treating physician would not prescribe radiation or additional radiation treatments~* patients who refuse additional radiation therapy.~* Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication~* Targeted bone/tumor interface are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)~* Targeted bone/tumor interface (most painful lesion) size up to 55 cm2 in surface area~* Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.~* Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible~* Able to communicate sensations during the ExAblate treatment~* Patients on ongoing chemotherapy regimen at the time of eligibility:~  1. with same chemotherapy regime (as documented from patient medical dossier), And~ 2. Worst pain NRS still ≥ 4 And~ 3. do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study.~Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.~* No radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration.~* Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated.~* Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).~Exclusion Criteria:~* Patients who either~* Need surgical stabilization of the affected bony structure (\>7 fracture risk score, see Section 7.4) OR~* Targeted tumor is at an impending fracture site (\>7 on fracture risk score, see Section 7.4).~OR~* Patients with surgical stabilization of tumor site with metallic hardware~* More than 5 painful lesions, or more than 1 requiring immediate localized treatment~* Targeted (treated) tumor is in the skull~* Patients on dialysis~* Patients with life expectancy \< 3-Months~* Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.~* Patients with unstable cardiac status including:~* Unstable angina pectoris on medication~* Patients with documented myocardial infarction within six months of protocol entry~* Congestive heart failure requiring medication (other than diuretic)~* Patients on anti-arrhythmic drugs~* Severe hypertension (diastolic BP \> 100 on medication)~* Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.~* Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.~* Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease~* KPS Score \< 60 (See Definitions below)~* Severe cerebrovascular disease (multiple CVA or CVA within 6 months)~* Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)~* Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.~* Are participating or have participated in another clinical trial in the last 30 days~* Patients initiating a new chemotherapy regime for pain purposes only, or radiation (for the targeted most painful lesion) within the last 2 weeks Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.~* Patients unable to communicate with the investigator and staff.~* Patients with persistent undistinguishable pain (pain source unidentifiable of the targeted lesion)~* Patient whose bone-lesion interface is \< 10-mm from the skin~* Targeted (most painful) tumor NOT visible by non-contrast MRI,~* Targeted (most painful) tumor Not accessible to ExAblate~* The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ExAblate Test Arm (Type: EXPERIMENTAL): Focused Ultrasound Surgery delivered by ExAblate MRgFUS

Based on this trial design, predict the completion outcome and termination type (if applicable).